Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Current Deferred Revenue (2021 - 2023)

InMed Pharmaceuticals' Current Deferred Revenue history spans 3 years, with the latest figure at $28656.0 for Q4 2023.

  • For Q4 2023, Current Deferred Revenue rose 77.21% year-over-year to $28656.0; the TTM value through Dec 2023 reached $28656.0, up 77.21%, while the annual FY2023 figure was $16171.0, N/A changed from the prior year.
  • Current Deferred Revenue reached $28656.0 in Q4 2023 per INM's latest filing, up from $16171.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $28656.0 in Q4 2023 to a low of $8390.0 in Q4 2021.
  • Average Current Deferred Revenue over 3 years is $15737.3, with a median of $16171.0 recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: surged 92.74% in 2022, then surged 77.21% in 2023.
  • A 3-year view of Current Deferred Revenue shows it stood at $8390.0 in 2021, then soared by 92.74% to $16171.0 in 2022, then soared by 77.21% to $28656.0 in 2023.
  • Per Business Quant, the three most recent readings for INM's Current Deferred Revenue are $28656.0 (Q4 2023), $16171.0 (Q2 2023), and $16171.0 (Q1 2023).